The cell therapy market is valued at 15 billion dollars and is set to double in value by 2030. Cell therapy has been instrumental in the development of treatments like […]
A decade ago, the emergence of new immunotherapies in the cell and gene therapy (CGT) space opened up new avenues to treat disease, sparking excitement across the industry. However, the […]
Mobilized peripheral blood has now surpassed bone marrow as the preferred source of CD34+ hematopoietic stem and progenitor cells (HSPCs) for allogeneic hematologic transplantation and translational medicines because both the […]
Hematopoietic stem cells (HSCs) have immense therapeutic potential because of their ability for both self-renewal and multi-lineage differentiation to maintain hematopoietic homeostasis. This rare population of cells are characterized by […]
Cell and gene therapies represent an expanding category of transformative medicines with the potential to change the way we treat human diseases. Broadly, these novel therapies include both in vivo […]
Growth in the Regenerative Medicine Field The regenerative medicine sector is on track for another watershed year where clinical progress, continued growth, and segmentation into new disease areas affecting larger […]
Expansion of GMP capabilities to support the rapidly growing cell and gene therapy industry AllCells Alameda, CA Expands GMP Processing Capabilities AllCells, the industry leader in the procurement and customization […]
Welcome to the second installment of our FAQ blog series! Today, we are looking at differences between CD34+ cells isolated from different tissue sources to provide a better understanding of […]
Copyright ©
AllCells. All rights reserved.
